Login
$LXEO
$3.23 +$0.00 (0.0%) After hours

Company Executives

Officer Age In this role 2025 pay Source
R. Nolan Townsend Also a director
Chief Executive Officer and Director
46 Not stated $3,650,940
Louis Tamayo
Chief Financial Officer
50 Since 2025
1 year
$1,665,915
Jose Manuel Otero
Chief Operating Officer
47 Since 2026
this year
Not reported
Narinder Bhalla
Chief Medical Officer
62 Since 2026
this year
Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
9
serving now
Independent
8 of 9
stated in the proxy
Director Independent Committees 2025 pay Source
R. Nolan Townsend
Not independent None stated Paid as CEO
Mette Kirstine Agger
Independent
Audit Committee Nominating and Corporate Governance Committee · Chair
$140,861
Steven Altschuler
Independent
Compensation Committee Science and Technology Committee
$163,361
Paula HJ Cholmondeley
Independent
Audit Committee · Chair
$140,975
Brenda Cooperstone
Independent
Nominating and Corporate Governance Committee Science and Technology Committee · Chair
$139,361
Reinaldo Diaz
Independent
Audit Committee Compensation Committee · Chair
$140,861
Laura Sepp-Lorenzino
Independent
Science and Technology Committee
Not stated
Toga Tanguler
Independent
Compensation Committee
Not stated
Tim Van Hauwermeiren
Independent
Nominating and Corporate Governance Committee
$120,579

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

1 disclosed in the proxy filed Apr 30, 2026
Dr. Eric Adler
former Chief Medical Officer and Head of Research and an executive officer; co-founder of Stelios and a selling shareholder
Approximately $1.3 million
third quarter of 2024

Share of the milestone payment to the selling shareholders of Stelios under the July 16, 2021 acquisition of Stelios by the company.

With Stelios Therapeutics Inc. Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support